Improved efficacies have led to a surge of interest in peptide drugs, classified by the U.S. FDA as biologics. As peptide drug discoveries proliferate, rather than allowing un-sustainable production methods turn the field into a victim of its own success, researchers aim to enhance peptide manufacturing. The bar set for sustainable peptide manufacturing requires it to be faster, cheaper, and more environmentally friendly than conventional methods.